ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,08621
0,06%
Bitcoin
70.265,86
0,19%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Palisade Bio Inc (PALI)

  7. Palisade Bio Inc (PALI) News

PALI

Palisade Bio (PALI)

Palisade Bio Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PALI
DatumZeitQuelleÜberschriftSymbolFirma
21/05/202414h30GlobeNewswire Inc.Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse ModelsNASDAQ:PALIPalisade Bio Inc
20/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PALIPalisade Bio Inc
17/05/202422h51Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PALIPalisade Bio Inc
16/05/202422h44Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
14/05/202414h05GlobeNewswire Inc.Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PALIPalisade Bio Inc
13/05/202422h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PALIPalisade Bio Inc
10/05/202422h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
10/05/202422h37Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:PALIPalisade Bio Inc
10/05/202422h37Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:PALIPalisade Bio Inc
09/05/202400h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
09/05/202400h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
08/05/202423h06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PALIPalisade Bio Inc
07/05/202414h30GlobeNewswire Inc.Palisade Bio Appoints Margery Fischbein to its Board of DirectorsNASDAQ:PALIPalisade Bio Inc
07/05/202413h30GlobeNewswire Inc.Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
02/05/202414h30GlobeNewswire Inc.Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
01/05/202414h30GlobeNewswire Inc.Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)NASDAQ:PALIPalisade Bio Inc
23/04/202414h30GlobeNewswire Inc.Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine ApproachNASDAQ:PALIPalisade Bio Inc
16/04/202414h30GlobeNewswire Inc.Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ StoolNASDAQ:PALIPalisade Bio Inc
11/04/202415h15GlobeNewswire Inc.Palisade Bio to Participate in the Virtual Investor Lunch Break EventNASDAQ:PALIPalisade Bio Inc
10/04/202414h15GlobeNewswire Inc.Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™NASDAQ:PALIPalisade Bio Inc
03/04/202423h30GlobeNewswire Inc.Palisade Bio Announces 1-for-15 Reverse Stock SplitNASDAQ:PALIPalisade Bio Inc
27/03/202413h00GlobeNewswire Inc.Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:PALIPalisade Bio Inc
06/03/202422h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
15/02/202414h35GlobeNewswire Inc.Palisade Bio to Present at Digestive Disease Week (DDW) 2024NASDAQ:PALIPalisade Bio Inc
14/02/202420h54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PALIPalisade Bio Inc
14/02/202402h10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PALIPalisade Bio Inc
13/02/202422h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
13/02/202421h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
13/02/202421h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
13/02/202421h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
 Showing the most relevant articles for your search:NASDAQ:PALI

Kürzlich von Ihnen besucht

NYSE
KO
Coca Cola
TG
LHA
Deutsche Lufthansa
USOTC
ADDYY
Adidas (QX)
NYSE
NKE
Nike
AMEX
XLE
Energy Select Sector SPDR
PM
XAUUSD
Gold vs US Dollar
FX
EURJPY
Euro vs Yen
USOTC
BASFY
BASF (QX)
NASDAQ
MSFT
Microsoft
FX
EURGBP
Euro vs Sterling
FX
EURUSD
Euro vs US Dollar
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AAPL
Apple
TG
RHM
Rheinmetall
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten